Exicure (NASDAQ:XCUR) Releases Earnings Results, Beats Expectations By $18.42 EPS

Exicure (NASDAQ:XCUR) posted its earnings results on Friday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($18.60) by $18.42, FiscalAI reports.

Exicure Trading Down 4.6%

XCUR stock traded down $0.06 during mid-day trading on Friday, reaching $1.25. 21,837 shares of the stock traded hands, compared to its average volume of 178,996. Exicure has a 52-week low of $1.18 and a 52-week high of $9.48. The stock’s fifty day moving average is $1.99 and its 200-day moving average is $3.16. The company has a market cap of $7.96 million, a P/E ratio of -0.81 and a beta of 3.65.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Exicure Company Profile

Exicure is a clinical?stage biotechnology company pioneering the development of next?generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology?based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard?to?reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.